此页面是自动翻译的，不保证翻译的准确性。请参阅 英文版 对于源文本。

Educational Intervention for Hypertension Management

2021年9月10日 更新者：Prof. Dr. Tariq Ashraf、University of Karachi

Impact of Educational Intervention on Hypertension Management by Primary Care Physician (Pump)

An interventional study is designed and a structured educational session will be conducted regarding the management of Blood pressure for the general physicians of Karachi, Lahore, Peshawar, Islamabad, Multan and Quetta. The purpose of designing this study is to observe the effect of hypertension educational intervention for general physicians to improve patient outcomes indirectly. Results of this study may provide a basis for developing a hypertension educational program targeted at general physicians.

研究概览

地位

尚未招聘

条件

干预/治疗

详细说明

Study Procedure

  1. Screening of General physicians as per inclusion criteria and recruitment of GPs by clinical research associate after obtaining informed consent form.
  2. GPs will be asked to fill hypertension awareness questionnaire at baseline
  3. Both group of GPs with the help of clinical research associate will recruit 5 patients from study site.
  4. After obtaining informed consent, Patient will be asked to fill hypertension awareness questionnaire at baseline or recruitment day and share pictures of 12-hour blood pressure measurement (from digital BP apparatus) with clinical research associate.
  5. Randomization of GPs will be than in to 2 Groups.
  6. After randomization, Group 1 GPs will receive (1 day) face to face education and Group 2 GPs will receive print version of education material.
  7. After GPs education intervention, patients will be invited for regular checkup at GPs clinic.
  8. Patient will be again asked to fill hypertension awareness questionnaire after 3 months and share pictures of 12-hour blood pressure measurement (from digital BP apparatus) with clinical research associate. (1st, 2nd & 3rd Month).
  9. GPs will be asked to fill hypertension awareness questionnaire again after 3 months (Post intervention)

研究类型

介入性

注册 (预期的)

126

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。

学习联系方式

学习地点

  • 巴基斯坦
    • Sindh
      • Karachi、Sindh、巴基斯坦、78500
        • Karachi institute of heart disease
        • 接触：
          • Tariq Ashraf, FCPS
          • 电话号码：03222999914

参与标准

研究人员寻找符合特定描述的人，称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 60年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • GPs who have at least three years of practice experience in the broad disciplines of primary care using the Numerical Pain Rating (NPR) scale over the past week ≥ 2 on a 0-10 numerical pain scale.
  • Patients between 18-60 years.
  • Patients with uncontrolled blood pressure according to Pakistan hypertension league guidelines
  • Patients with or without angiographically proven coronary, peripheral or cerebral vascular disease.
  • Patients must be able to give informed consent and be able to read and comprehend in the Urdu (National Language)
  • Patients must have a digital BP apparatus at home.
  • Patients must have a phone with camera and internet.

Exclusion Criteria:

  • GPs who had attended a planned Hypertension educational program during the last 6 months.
  • Patients with a recognized psychiatric disorder as per the Diagnostic and Statistical Manual of Mental Disorders

学习计划

本节提供研究计划的详细信息，包括研究的设计方式和研究的衡量标准。

研究是如何设计的？

设计细节

  • 主要用途：支持治疗
  • 分配：随机化
  • 介入模型：并行分配
  • 屏蔽：单身的

武器和干预

参与者组/臂
干预/治疗
实验性的：Interventional group
GPs of the Interventional group will receive (1 day) face to face education with structured educational material on strategies of hypertension management by a senior cardiologist.
其他：Face to face Educational Training
  1. Key points of current hypertension guidelines.
  2. 10-step checklist how to obtain standardized upper arm blood pressure readings according to guidelines.
  3. template of a blood pressure documentation sheet for serial documentation of blood pressure values by patients.
  4. checklists to assist in the diagnosis of secondary hypertension.
  5. Patient information leaflet about hypertension.
有源比较器：Control group
GPs of the Control group will receive print version of education material (Structured educational material) on strategies of structured hypertension management.
其他：Printed Education Material
  1. Key points of current hypertension guidelines.
  2. 10-step checklist how to obtain standardized upper arm blood pressure readings according to guidelines.
  3. template of a blood pressure documentation sheet for serial documentation of blood pressure values by patients.
  4. checklists to assist in the diagnosis of secondary hypertension.
  5. Patient information leaflet about hypertension.

研究衡量的是什么？

主要结果指标

结果测量
措施说明
大体时间
Blood Pressure
大体时间：3 Months
Pre & Post change in the blood pressure control rate. Defined as percentage of patients with an average 12-hour blood pressure <130/80 mmHg.
3 Months

次要结果测量

结果测量
措施说明
大体时间
Knowledge of GPs about Hypertension Management
大体时间：3 Months
Pre & Post knowledge enhancement of GPs regarding hypertension management.
3 Months
Knowledge of Patients about Hypertension Management
大体时间：3 Months
Pre & Post knowledge enhancement of patients regarding hypertension
3 Months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

University of Karachi

合作者

Advanced Education & Research Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查，以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (预期的)

2021年9月30日

初级完成 (预期的)

2022年12月31日

研究完成 (预期的)

2022年12月31日

研究注册日期

首次提交

2021年8月22日

首先提交符合 QC 标准的

2021年9月2日

首次发布 (实际的)

2021年9月9日

研究记录更新

最后更新发布 (实际的)

2021年9月17日

上次提交的符合 QC 标准的更新

2021年9月10日

最后验证

2021年9月1日

更多信息

与本研究相关的术语

关键字

其他相关的 MeSH 术语

其他研究编号

  • PUMPKG

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.

Face to face Educational Training的临床试验

搜索类似试验

赞助者和合作者

医疗条件

药物干预

CROs by country

CROs in Dominican Republic

条件

罕见疾病

药物干预

膳食补充剂

赞助者/合作者

地点

3
订阅